Matching articles for "Cefaly"
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • October 5, 2020; (Issue 1608)
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute
treatment of mild to moderate migraine headache
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine headache pain in most patients without
vascular disease. Early treatment of pain when it is
still mild to moderate in intensity improves headache
response and reduces the risk of recurrence.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use...
An oral nonopioid analgesic may be sufficient for
treatment of mild to moderate migraine without severe
nausea or vomiting. A triptan is the drug of choice for
treatment of moderate to severe migraine. Use of
a triptan early in an attack when pain is still mild to
moderate in intensity improves headache response
and reduces recurrence rates.
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)
The Medical Letter on Drugs and Therapeutics • February 13, 2017; (Issue 1514)
...
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • August 18, 2014; (Issue 1449)
The FDA has approved the use of a transcutaneous
electrical nerve stimulation device (Cefaly – Cefaly
Technology) for prevention of episodic migraine in
patients ≥18 years old. The first device to be...
The FDA has approved the use of a transcutaneous
electrical nerve stimulation device (Cefaly – Cefaly
Technology) for prevention of episodic migraine in
patients ≥18 years old. The first device to be approved
in the US for migraine prevention, it is available in
Canada and Europe for treatment and prevention of
migraines. A transcranial magnetic stimulation device
(SpringTMS - eNeura Therapeutics) recently approved
by the FDA for treatment of migraine preceded by aura
will be reviewed in a future issue.